Registered title, quoted from ClinicalTrials.gov
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fujian Cancer Hospital; 2 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
- Study siteSecond Affiliated Hospital of Fujian Medical University福建医科大学附属第二医院QuanzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07691333, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Female patients with breast cancer aged ≥18 and ≤75 years, satisfying one of the following menopausal status criteria: (1) Bilateral oophorectomy in medical history, or age ≥60 years; (2) Age <60 years with natural menopause (defined as spontaneous cessation of regular menses for at least 12 consecutive months without other pathological or physiological causes), with postmenopausal levels of E2 and FSH; (3) Pre-menopausal or peri-menopausal female patients who are willing to receive LHRH agonist therapy throughout the study period.
Inclusion criterion 1
Histopathologically confirmed estrogen receptor (ER)-positive (>10%) and/or progesterone receptor (PR)-positive (>10%), HER2-negative breast cancer, assessed in accordance with the 2018 ASCO-CAP guidelines. HER2 negativity is defined as immunohistochemistry (IHC) score of 0+, or IHC 2+ with negative in situ hybridization (ISH) test (ISH amplification ratio <2.0), verified by the pathological laboratory.
Inclusion criterion 2
Accept core needle biopsy to provide initial tissue samples with Ki-67 ≥10% tested on the initial specimen; agree to provide tissue samples for tumor biomarker testing and peripheral blood samples for biomarker analysis.
Inclusion criterion 3
Treatment-naïve breast cancer patients staged as Stage II-III per the 8th edition of the AJCC staging system.
Inclusion criterion 4
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Inclusion criterion 5
Breast cancer without histopathological confirmation, or refusal to undergo breast core needle biopsy before or during study treatment.
Exclusion criterion 5
History of other malignant tumors within the previous 5 years, except for cured carcinoma in situ of the cervix.
Exclusion criterion 6
Known hypersensitivity to any components of the study regimen; history of immunodeficiency diseases, including positive human immunodeficiency virus (HIV) test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.
Exclusion criterion 10
Pregnant or breastfeeding female patients; fertile women with a positive baseline pregnancy test result, or fertile women unwilling to use effective contraception throughout the entire trial period.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07691333, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
-
Patients who meet all of the following inclusion criteria are eligible for enrollment in this trial:
- Female patients with breast cancer aged ≥18 and ≤75 years, satisfying one of the following menopausal status criteria: (1) Bilateral oophorectomy in medical history, or age ≥60 years; (2) Age <60 years with natural menopause (defined as spontaneous cessation of regular menses for at least 12 consecutive months without other pathological or physiological causes), with postmenopausal levels of E2 and FSH; (3) Pre-menopausal or peri-menopausal female patients who are willing to receive LHRH agonist therapy throughout the study period.
- Histopathologically confirmed estrogen receptor (ER)-positive (>10%) and/or progesterone receptor (PR)-positive (>10%), HER2-negative breast cancer, assessed in accordance with the 2018 ASCO-CAP guidelines. HER2 negativity is defined as immunohistochemistry (IHC) score of 0+, or IHC 2+ with negative in situ hybridization (ISH) test (ISH amplification ratio <2.0), verified by the pathological laboratory.
- Accept core needle biopsy to provide initial tissue samples with Ki-67 ≥10% tested on the initial specimen; agree to provide tissue samples for tumor biomarker testing and peripheral blood samples for biomarker analysis.
- Treatment-naïve breast cancer patients staged as Stage II-III per the 8th edition of the AJCC staging system.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ function as defined below: Hematologic function: ① Absolute neutrophil count (ANC) ≥1.5×10⁹/L (no growth factor administered within 14 days prior to screening); ② Platelet count ≥100×10⁹/L (no corrective hematologic therapy within 7 days prior to screening); ③ Hemoglobin ≥100 g/L (no corrective hematologic therapy within 7 days prior to screening).
Hepatic and renal function: ① Total bilirubin ≤1×upper limit of normal (ULN); ② Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN (ALT and AST ≤5×ULN for patients with liver metastases); ③ Blood urea nitrogen and serum creatinine ≤1.5×ULN, with creatinine clearance ≥50 mL/min (calculated by the Cockcroft-Gault formula).
- Cardiac function on echocardiogram: left ventricular ejection fraction (LVEF) ≥50%. 12-lead electrocardiogram (ECG): QT interval ≤480 ms.
- Able to provide written informed consent prior to any study-related procedures.
Exclusion Criteria:
-
Patients presenting with any of the following conditions are ineligible for enrollment in this study:
- Prior receipt of any form of anti-tumor therapy (including chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.).
- Concurrent administration of other anti-tumor agents.
- Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer.
- Stage IV breast cancer.
- Breast cancer without histopathological confirmation, or refusal to undergo breast core needle biopsy before or during study treatment.
- History of other malignant tumors within the previous 5 years, except for cured carcinoma in situ of the cervix.
- Severe dysfunction of vital organs including the heart, liver and kidneys.
- Conditions interfering with oral drug intake and absorption, such as inability to swallow, chronic diarrhea, or intestinal obstruction.
- Participation in another interventional clinical trial within 4 weeks prior to enrollment.
- Known hypersensitivity to any components of the study regimen; history of immunodeficiency diseases, including positive human immunodeficiency virus (HIV) test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.
- Prior diagnosis of any cardiac disease, including clinically significant arrhythmias requiring medical intervention, myocardial infarction, heart failure, or any other cardiac disease judged by the investigator to render the patient unsuitable for trial participation.
- Pregnant or breastfeeding female patients; fertile women with a positive baseline pregnancy test result, or fertile women unwilling to use effective contraception throughout the entire trial period.
- Coexisting severe medical conditions that may compromise patient safety or interfere with study completion as assessed by the investigator, including but not limited to uncontrolled severe hypertension, uncontrolled severe diabetes, active infections, etc.
- Confirmed prior history of neurological or psychiatric disorders, including epilepsy or dementia.
- Any other conditions deemed by the investigator to make the patient unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07691333, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07691333, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.